Johnson & Johnson (JNJ-N) Stock Predictions - Stockchase
WATCH LIST
410
Johnson & Johnson (JNJ-N)

ON STOCKCHASE SINCE Oct 2000

biotechnology/pharmaceutical

Johnson & Johnson

JNJ-N

159 watching          
Join the Discussion

Johnson & Johnson (JNJ-N) SAVE Mar, 18, 2019, 3:34 pm

136.93 0.67 (0.49%)

About Johnson & Johnson (JNJ-N)

Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886. More at Wikipedia

What the experts are saying about JNJ-N



  • All
  • Filtered
Signal Opinion Expert
TOP PICK
Johnson & Johnson(JNJ-N) 

December 14, 2016

This is more broadly diversified than others in the pharmaceutical area. Pharmaceuticals is about 45% of their revenues. They have medical devices and diagnostics as well as their consumer products division. On the Pharma side, they have a very strong pipeline, and have identified 10 drugs that potentially have $1 billion revenue potential, that will be launching over the next 3 years. Attractively priced at about 16X forward earnings, below their market multiple. Dividend yield of 2.7%. Have consistently raised the dividend for 55 years.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This is more broadly diversified than others in the pharmaceutical area. Pharmaceuticals is about 45% of their revenues. They have medical devices and diagnostics as well as their consumer products division. On the Pharma side, they have a very strong pipeline, and have identified 10 drugs that potentially have $1 billion revenue potential, that will be launching over the next 3 years. Attractively priced at about 16X forward earnings, below their market multiple. Dividend yield of 2.7%. Have consistently raised the dividend for 55 years.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$114.990
Owned Owned
Yes

COMMENT
Johnson & Johnson(JNJ-N) 

December 13, 2016

With the pickup in financials, (which were really under owned by institutions, portfolio managers and investors), they looked at their holdings to see what they could sell, because there wasn’t a lot of new money coming into the market. A lot of the leading technology stocks and healthcare stocks sold off. In the last 2 weeks, we are starting to see net flows into equities, which could be the beginning of that great rotation that people talk about. Right now, healthcare is not one of the leading groups. There has been some tax loss selling, but feels we are getting towards the end of that. Some of these lagging groups are starting to bubble up. This is a great quality company.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

With the pickup in financials, (which were really under owned by institutions, portfolio managers and investors), they looked at their holdings to see what they could sell, because there wasn’t a lot of new money coming into the market. A lot of the leading technology stocks and healthcare stocks sold off. In the last 2 weeks, we are starting to see net flows into equities, which could be the beginning of that great rotation that people talk about. Right now, healthcare is not one of the leading groups. There has been some tax loss selling, but feels we are getting towards the end of that. Some of these lagging groups are starting to bubble up. This is a great quality company.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Burrows

President , Barometer Capital Ma...

Price Price
$115.890
Owned Owned
No

COMMENT
Johnson & Johnson(JNJ-N) 

December 7, 2016

There has recently been a massive rotation out of defensive areas, where you didn’t need to rely on GDP growth. This is a wonderful company. Trades between $100 and $120, and is probably going to trade in this range for a time. Large institutional companies will probably look at this as a source of cash, and looking elsewhere to deploy their capital. Dividend yield of 2.9%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

There has recently been a massive rotation out of defensive areas, where you didn’t need to rely on GDP growth. This is a wonderful company. Trades between $100 and $120, and is probably going to trade in this range for a time. Large institutional companies will probably look at this as a source of cash, and looking elsewhere to deploy their capital. Dividend yield of 2.9%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
James Thorne

Sr Portfol, Caldwell Investment ...

Price Price
$111.100
Owned Owned
Unknown

SELL
Johnson & Johnson(JNJ-N) 

December 1, 2016

This is expensive. It is at a very high valuation level on a Price to Book basis. His FMV was about $125 with a technical ceiling at about $130. Thinks the stock has pretty much had it, and he wouldn’t be invested in it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This is expensive. It is at a very high valuation level on a Price to Book basis. His FMV was about $125 with a technical ceiling at about $130. Thinks the stock has pretty much had it, and he wouldn’t be invested in it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ross Healy

Chairman, Strategic Analysis C...

Price Price
$111.380
Owned Owned
No

BUY
Johnson & Johnson(JNJ-N) 

November 29, 2016

A bond-like proxy for a stock portfolio. One of 3 publicly traded companies that still has an AAA rating credit. They have tremendous amounts of financing capabilities. They pay a nice dividend, and have grown it at a very high rate over the last decade. If they ever wanted to split the company up, they could unlock value in terms of their consumer business, their R&D, and their pharmacy business. This should be a core portion for any portfolio. Doesn’t think this is overly expensive.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A bond-like proxy for a stock portfolio. One of 3 publicly traded companies that still has an AAA rating credit. They have tremendous amounts of financing capabilities. They pay a nice dividend, and have grown it at a very high rate over the last decade. If they ever wanted to split the company up, they could unlock value in terms of their consumer business, their R&D, and their pharmacy business. This should be a core portion for any portfolio. Doesn’t think this is overly expensive.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John Petrides

Managing D, Point View Wealth Ma...

Price Price
$112.480
Owned Owned
Unknown

PAST TOP PICK
Johnson & Johnson(JNJ-N) 

November 29, 2016

(A Top Pick Nov 9/15. Up 15.52%.) He sold this in order to buy another stock. This is a great company, but has run up a lot in the last little while. Thinks it will move sideways for the next while. Dividend yield of 2.8%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick Nov 9/15. Up 15.52%.) He sold this in order to buy another stock. This is a great company, but has run up a lot in the last little while. Thinks it will move sideways for the next while. Dividend yield of 2.8%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Harris, CF

Portfolio , Avenue Investment Ma...

Price Price
$112.480
Owned Owned
No

COMMENT
Johnson & Johnson(JNJ-N) 

November 24, 2016

One of the world’s great businesses with their great consumer products business, medical devices and pharma. Shares have risen, so it is no longer a value stock, so he is not going to buy it here. This is a dividend raiser. They ran into a bit of an issue recently. They make Remicade for Crohn’s disease, and there is now a competitor coming out with a bio-similar Remicade. Not cheap enough for him.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

One of the world’s great businesses with their great consumer products business, medical devices and pharma. Shares have risen, so it is no longer a value stock, so he is not going to buy it here. This is a dividend raiser. They ran into a bit of an issue recently. They make Remicade for Crohn’s disease, and there is now a competitor coming out with a bio-similar Remicade. Not cheap enough for him.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Lorne Steinberg

President , Lorne Steinberg Weal...

Price Price
$113.070
Owned Owned
No

DON'T BUY
Johnson & Johnson(JNJ-N) 

November 1, 2016

There are 3 parts to their business; pharma, medical devices and consumer products. Medical devices are about 40%, and consumer products are about 20%. Unfortunately, that 60% has had fairly flat growth. The Pharma sector has really been the rock star. Each business would be large enough to stand alone, and you would be better off if the business was split into 3. Decent dividend of about 2.7%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

There are 3 parts to their business; pharma, medical devices and consumer products. Medical devices are about 40%, and consumer products are about 20%. Unfortunately, that 60% has had fairly flat growth. The Pharma sector has really been the rock star. Each business would be large enough to stand alone, and you would be better off if the business was split into 3. Decent dividend of about 2.7%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Kash Pashootan

CEO & Chie, First Avenue Investm...

Price Price
$115.340
Owned Owned
No

HOLD
Johnson & Johnson(JNJ-N) 

October 25, 2016

A well-run dominant business in many of its key brands from a consumer product standpoint as well as a big healthcare business. Not overly cheap. Has owned this in the past.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A well-run dominant business in many of its key brands from a consumer product standpoint as well as a big healthcare business. Not overly cheap. Has owned this in the past.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Colin Stewart

CEO & Port, JC Clark Investments...

Price Price
$113.960
Owned Owned
No

COMMENT
Johnson & Johnson(JNJ-N) 

October 25, 2016

(Market Call Minute.) This is a company that has been growing debt, buying back stock and increasing dividends. Ultimately hasn’t increased its revenue in 4 years.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(Market Call Minute.) This is a company that has been growing debt, buying back stock and increasing dividends. Ultimately hasn’t increased its revenue in 4 years.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John O'Connell,

Chairman a, Davis Rea...

Price Price
$113.960
Owned Owned
Unknown

COMMENT
Johnson & Johnson(JNJ-N) 

October 20, 2016

This would be in the category of a “forever” stock. A very, very consistent and diversified performer. The type of company that supports a constituent of the index that would respond well after the election. He looks for stocks that have higher returns on equity and higher growth rates than this company, but this is one that you could buy, put it away and forget about it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This would be in the category of a “forever” stock. A very, very consistent and diversified performer. The type of company that supports a constituent of the index that would respond well after the election. He looks for stocks that have higher returns on equity and higher growth rates than this company, but this is one that you could buy, put it away and forget about it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Del Vicar

Portfolio , HollisWealth...

Price Price
$114.870
Owned Owned
Unknown

HOLD
Johnson & Johnson(JNJ-N) 

October 19, 2016

One of the big, long term successful companies. The big reason for the stock drop lately is Remicade, its largest drug. Pfizer has something which is going to be priced 5%-10% cheaper. If you are going to be in any of the large cap healthcare stocks, this is the one.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

One of the big, long term successful companies. The big reason for the stock drop lately is Remicade, its largest drug. Pfizer has something which is going to be priced 5%-10% cheaper. If you are going to be in any of the large cap healthcare stocks, this is the one.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gavin Graham

Trustee, Pointbreak ETFs...

Price Price
$114.590
Owned Owned
Yes

BUY
Johnson & Johnson(JNJ-N) 

October 19, 2016

Drug companies and medical companies have been under a lot of pressure, and a lot of it is politically driven. The US has the highest cost for drugs globally, but also has the most number of pharmaceutical companies. This one is very diversified. His understanding of the California proposition 61 is for regulating drug prices. California kind of leads the nation in terms of propositions. Overall though, this is a fabulous company, and he would use this weakness as an opportunity to Buy.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Drug companies and medical companies have been under a lot of pressure, and a lot of it is politically driven. The US has the highest cost for drugs globally, but also has the most number of pharmaceutical companies. This one is very diversified. His understanding of the California proposition 61 is for regulating drug prices. California kind of leads the nation in terms of propositions. Overall though, this is a fabulous company, and he would use this weakness as an opportunity to Buy.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John Stephenson

President , Stephenson & Company...

Price Price
$114.590
Owned Owned
Unknown

DON'T BUY
Johnson & Johnson(JNJ-N) 

October 18, 2016

He would run away.  They are a good offering but the valuation is a little too high.  People gravitate towards what they think is quality.  It is trading at 20 times earnings and have low growth.  He prefers others. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He would run away.  They are a good offering but the valuation is a little too high.  People gravitate towards what they think is quality.  It is trading at 20 times earnings and have low growth.  He prefers others. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$115.410
Owned Owned
Unknown

HOLD
Johnson & Johnson(JNJ-N) 

October 17, 2016

One of the few healthcare companies that has held up. There are no catalysts, however.  It is a very solid company that pays a good dividend and has growing earnings. Stick with a winner.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

One of the few healthcare companies that has held up. There are no catalysts, however.  It is a very solid company that pays a good dividend and has growing earnings. Stick with a winner.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ian Shaffer

President, Galliant Advisors...

Price Price
$118.490
Owned Owned
Unknown

Showing 61 to 75 of 410 entries
Successfully Saved Company
Successfully Saved Company
8+
JOIN THE DISCUSSION
8 comments in the last 7 days